| Trial ID: | L4045 |
| Source ID: | NCT06830096
|
| Associated Drug: |
5 Mg Glipizide Ingestion
|
| Title: |
Role of KATP Channel Loss in Type 2 Diabetes
|
| Acronym: |
BC
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Obesity and Type 2 Diabetes
|
| Interventions: |
DRUG: 5 mg glipizide ingestion
|
| Outcome Measures: |
Primary: Insulin secretion, Insulin secreted by pancreas into plasma measured over 90 minutes after glipizide ingestion. Insulin secretion will be calculated using a stepwise insulin secretion rate function to fit plasma C-peptide concentrations to a two-compartment model of C-peptide kinetics using population-based C-peptide model parameters., 90 minutes after glipizide ingestion |
|
| Sponsor/Collaborators: |
Sponsor: Washington University School of Medicine | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2025-03-03
|
| Completion Date: |
2026-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-19
|
| Locations: |
Washington University in St. Louis, Saint Louis, Missouri, 63110, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06830096
|
